Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. The company is headquartered in Emeryville, California and currently employs 202 full-time employees. The company went IPO on 2024-02-09. The firm is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). The company has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The firm uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
The most recent EPS for Metagenomi Therapeutics Inc is $-0.6, not beating expectations of $-0.61.
How did Metagenomi Therapeutics Inc MGX's revenue perform in the last quarter?
Metagenomi Therapeutics Inc revenue for the last quarter is $-0.6
What is the revenue estimate for Metagenomi Therapeutics Inc?
According to 4 of Wall street analyst, the revenue estimate of Metagenomi Therapeutics Inc range from $10.5M to $4.6M
What's the earning quality score for Metagenomi Therapeutics Inc?
Metagenomi Therapeutics Inc has a earning quality score of B+/45.605778. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Metagenomi Therapeutics Inc report earnings?
Metagenomi Therapeutics Inc next earnings report is expected in 2026-06-03
What are Metagenomi Therapeutics Inc's expected earnings?
Metagenomi Therapeutics Inc expected earnings is $6.81M, according to wall-street analysts.
Did Metagenomi Therapeutics Inc beat earnings expectations?
Metagenomi Therapeutics Inc recent earnings of $3.91M does not beat expectations.